Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 INDOCO REMEDIES   MYLAN
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-23
MYLAN
Dec-18
INDOCO REMEDIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4233,945-   
Low Rs3082,171-   
Sales per share (Unadj.) Rs181.11,815.3-  
Earnings per share (Unadj.) Rs15.449.3-  
Cash flow per share (Unadj.) Rs23.1389.2-  
Dividends per share (Unadj.) Rs2.250-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs111.51,963.8-  
Shares outstanding (eoy) m92.15514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.01.7 119.8%   
Avg P/E ratio x23.762.0 38.2%  
P/CF ratio (eoy) x15.87.9 201.4%  
Price / Book Value ratio x3.31.6 210.5%  
Dividend payout %14.60-   
Avg Mkt Cap Rs m33,6831,573,481 2.1%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m3,2260-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m16,686933,975 1.8%  
Other income Rs m240-   
Total revenues Rs m16,710933,975 1.8%   
Gross profit Rs m2,860241,678 1.2%  
Depreciation Rs m706174,877 0.4%   
Interest Rs m25044,921 0.6%   
Profit before tax Rs m1,92821,880 8.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m505-3,481 -14.5%   
Profit after tax Rs m1,42325,361 5.6%  
Gross profit margin %17.125.9 66.2%  
Effective tax rate %26.2-15.9 -164.8%   
Net profit margin %8.52.7 314.0%  
BALANCE SHEET DATA
Current assets Rs m8,082521,531 1.5%   
Current liabilities Rs m4,245380,253 1.1%   
Net working cap to sales %23.015.1 152.0%  
Current ratio x1.91.4 138.8%  
Inventory Days Days2584 30.0%  
Debtors Days Days76893 822.7%  
Net fixed assets Rs m9,055181,176 5.0%   
Share capital Rs m184497 37.1%   
"Free" reserves Rs m10,0920-   
Net worth Rs m10,2761,010,390 1.0%   
Long term debt Rs m1,4351,090,535 0.1%   
Total assets Rs m17,1372,710,259 0.6%  
Interest coverage x8.71.5 585.2%   
Debt to equity ratio x0.11.1 12.9%  
Sales to assets ratio x1.00.3 282.5%   
Return on assets %9.82.6 376.4%  
Return on equity %13.82.5 551.5%  
Return on capital %18.63.2 585.0%  
Exports to sales %47.50-   
Imports to sales %11.50-   
Net fx Rs m6,0020-   
CASH FLOW
From Operations Rs m1,788194,080 0.9%  
From Investments Rs m-2,082-100,318 2.1%  
From Financial Activity Rs m228-90,414 -0.3%  
Net Cashflow Rs m-651,608 -4.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare INDOCO REMEDIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare INDOCO REMEDIES With: SMS PHARMA  NGL FINE CHM  ISHITA DRUGS  PARENT.DRUGS  TRIDENT LIFELINE  



Today's Market

Why Adani Group Stocks are Falling | Baazar Style Retail Files for IPO | Top Buzzing Stocks Today Why Adani Group Stocks are Falling | Baazar Style Retail Files for IPO | Top Buzzing Stocks Today(Pre-Open)

On Monday, Indian share markets reversed the trend as the session progressed and ended the day higher.